A phase 2 Proof-of-Concept study of ABX-002 in treatment of Treatment Resistant Depression (TRD)
Latest Information Update: 12 Sep 2022
At a glance
- Drugs ABX-002 (Primary)
- Indications Depression
- Focus Proof of concept; Therapeutic Use
- Sponsors Autobahn Therapeutics
Most Recent Events
- 12 Sep 2022 New trial record
- 08 Sep 2022 According to an Autobahn Therapeutics media release, the company has raised 32.7 Million Dollars to supports advancement of ABX-002 through Phase 2 Proof-of-Concept clinical study in Treatment Resistant Depression.